NKp46 NKCE

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNKp46 NKCE

Drug Alias NameNKp46-NKCENKp46 NKCE

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionNatural cytotoxicity triggering receptor 1 inhibitorsFCGR3A (CD16a) NK-cell engagers

TargetsNatural cytotoxicity triggering receptor 1Low affinity immunoglobulin gamma Fc region receptor III-A

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInnate Pharma

China Registration ClassN/A

Develop Information

Active CompaniesInnate Pharma

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A